دورية أكاديمية
Degree of serum LDL cholesterol reduction by simvastatin and ezetimibe is dependent on baseline LDL cholesterol concentration but not on baseline values and changes in cholesterol synthesis and absorption parameters.
| العنوان: | Degree of serum LDL cholesterol reduction by simvastatin and ezetimibe is dependent on baseline LDL cholesterol concentration but not on baseline values and changes in cholesterol synthesis and absorption parameters. |
|---|---|
| المؤلفون: | Lütjohann D, Stellaard F |
| المصدر: | International journal of clinical pharmacology and therapeutics [Int J Clin Pharmacol Ther] 2024 Jul; Vol. 62 (7), pp. 295-306. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Dustri-Verlag Dr. K. Feistle Country of Publication: Germany NLM ID: 9423309 Publication Model: Print Cited Medium: Print ISSN: 0946-1965 (Print) Linking ISSN: 09461965 NLM ISO Abbreviation: Int J Clin Pharmacol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Munchen : Dustri-Verlag Dr. K. Feistle Original Publication: München : Dustri-Verlag Dr. K. Feistle, c1994- |
| مواضيع طبية MeSH: | Cholesterol, LDL*/blood , Simvastatin*/pharmacology , Simvastatin*/therapeutic use , Anticholesteremic Agents*/pharmacology , Anticholesteremic Agents*/therapeutic use , Ezetimibe*/therapeutic use , Ezetimibe*/pharmacology , Cholesterol*/blood , Cholesterol*/biosynthesis , Hypercholesterolemia*/drug therapy , Hypercholesterolemia*/blood, Humans ; Male ; Adult ; Middle Aged ; Drug Therapy, Combination ; Intestinal Absorption/drug effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use |
| مستخلص: | Objective: We questioned whether the baseline status of low-density lipoprotein cholesterol (LDL-C), cholesterol synthesis and absorption, and the changes in these parameters determine the change in serum LDL-C under statin or ezetimibe treatment or under combination treatment. Materials and Methods: 37 mildly hypercholesterolemic healthy male subjects were studied under placebo, simvastatin (20 mg/d), ezetimibe (10 mg/d), and combination treatment. We correlated the change of LDL-C (ΔLDL-C) under treatment with the placebo end values of LDL-C (baseline), whole-body cholesterol synthesis, and hepatic cholesterol synthesis (serum lathosterol to cholesterol ratio) as well as fractional absorption rate (FAR) of cholesterol and serum campesterol to cholesterol ratio. The change in serum LDL-C was also correlated with the changes in synthesis and absorption parameters. Results: ΔLDL-C was highly negatively related to baseline LDL-C under ezetimibe (p < 0.0001), simvastatin (p < 0.0001), and combination treatment (p < 0.0001). Under combination treatment, LDL-C lowering appears possible from baseline values of 10 mg/dL upwards, while ΔLDL-C was independent of the baseline value (-50 to -60%). ΔLDL-C was positively associated with placebo FAR under ezetimibe (p = 0.0106) and combination treatment (p = 0.0457). No associations were found between ΔLDL-C and baseline values for synthesis nor between ΔLDL-C and changes in synthesis and absorption surrogate markers. Conclusion: Under ezetimibe, simvastatin, and combination treatment, ΔLDL-C is predominantly dependent on the baseline LDL-C concentration. We hypothesize that the concentration gradient between serum LDL-C and hepatic cellular cholesterol determines the efficiency of serum LDL-C lowering. Combination treatment is the preferred treatment. |
| المشرفين على المادة: | 0 (Cholesterol, LDL) AGG2FN16EV (Simvastatin) 0 (Anticholesteremic Agents) EOR26LQQ24 (Ezetimibe) 97C5T2UQ7J (Cholesterol) 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors) |
| تواريخ الأحداث: | Date Created: 20240503 Date Completed: 20240625 Latest Revision: 20240625 |
| رمز التحديث: | 20240625 |
| DOI: | 10.5414/CP204536 |
| PMID: | 38699976 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0946-1965 |
|---|---|
| DOI: | 10.5414/CP204536 |